Actinium Pharmaceuticals Inc (NYSE: ATNM) announced data from its Phase III study of Iomab-B at the meetings of the Centre for International Blood and Marrow Transplant and the American Society for Transplantation and Cellular Therapy. The meeting took from between April 23 and April 26 in Utah.
How the company conducted the study
During the oral presentation, a spokesperson for the company presented key data from its study. The company stated that the trial had consisted of 66 patients, which it gave Iomab-B. These patients got bone marrow transplants and engagements after receiving the drug.
The control group had 77 patients. These patients were given the standard of care. Only 14 of them proceeded to a bone marrow transplant. One of them experienced graft failure. Some of the patients in the control group were given Iomab-B when they didn’t get complete remission from the drugs offered in the control. These patients achieved remission with the new compound.
Patients who received Iomab-B were also less likely to get sepsis. About 5% of them experienced sepsis in comparison with 24% in the other group. The patients receiving Iomab-B were also less likely to develop febrile neutropenia (34%).
According to the CMO of Actinium Pharmaceuticals, Avinash Desai, M.D, the people present at the oral presentation were pleased with the findings from the Iomab-B study as it indicated the drug’s potential. He adds that patients with refractory or relapsed Acute Myeloid Leukaemia (AML) have little access to bone marrow transplants. For this reason, they have a high mortality rate.
The drug was more effective than standard therapies
Dr Desai states that the treatment for these patients is not as impactful as evidenced by their use in the study’s control group. Iomab-B is the first therapy to produce high radiation amounts to the bone marrow and cancer cells for conditioning and induction.
The CEO and Chairman of Actinium, Sandesh Seth, states that the study indicated increased BMT access, safety, and engraftment, thus validating the company’s belief in Iomab-B. Seth states that the company was excited to see similar results in patients given the compound. Moreover, the positive results will encourage Actinium to develop Iomab-B for patients with AML further.
